# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Iterum announced that a meeting of the FDA Antimicrobial Drugs Advisory Committee (AMDAC) took place on September 9, 2024 at wh...
HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $5 price target.
HC Wainwright & Co. analyst Ed Arce maintains Iterum Therapeutics (NASDAQ:ITRM) with a Buy and lowers the price target f...
Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing ne...
Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing ne...